Novo Nordisk Reports Q3 2026 Growth Driven by GLP-1 Portfolio and Wegovy Expansion
Novo Nordisk (NVO) reported strong third-quarter results for 2026, with adjusted sales reaching DKK 79.2 billion, a 4% increase at constant exchange rates. This growth was primarily fueled by volume gains within its GLP-1 portfolio, particularly in the obesity segment which saw 22% sales growth. The company's adjusted operating profit rose significantly to DKK 32 billion, representing a 27% increase compared to the previous year. The company upgraded its full-year 2026 guidance for both adjusted sales and operating profit due to increased expectations for GLP-1 product sales. While facing price erosion in the U.S. market—specifically 30% to 35% for Wegovy—Novo Nordisk maintained strong market leadership, with Wegovy capturing over 50% of new-to-brand prescriptions in the U.S. and a 54% international GLP-1 market share.
Tickers: $NVO